No Data
Hong Kong stocks movement | KEYMED BIO-B (02162) once dropped over 10%, currently experiencing seven consecutive days of decline. It is reported that the company's competitor's medical insurance renewal price drop exceeded expectations.
KEYMED BIO-B (02162) has fallen more than 10%, with its stock price currently showing a seven-day decline. As of the time of writing, it has dropped 6.38%, priced at 30.8 Hong Kong dollars, with a transaction amount of 95.3227 million Hong Kong dollars.
The upward momentum has been interrupted, with KEYMED BIO-B (02162) experiencing six consecutive declines due to rumors of price cuts by competitors.
Recently, an unconfirmed news about Dupilumab's medical insurance renewal price drop exceeding expectations has spread quietly in the market, and this seems to be the main reason for the recent sharp decline in Cangnuoya's stock price.
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
[Brokerage Focus] Guozheng International: Innovative drug companies and medical instruments companies are expected to continuously expand their market ceiling by going overseas.
Jingwu Financial News | Guozheng International reports that looking towards 2025, as the Federal Reserve begins a rate cut cycle, combined with the high premium rate of A-shares over H-shares, the cost-effectiveness of Hong Kong stocks is becoming more pronounced, leading to improved liquidity. For the Pharmaceutical Sector, with the continuous advancement of the "medical insurance + commercial insurance" model and policy support, the scale of the Industry is expected to further expand. The bank is Bullish on three major investment themes driven by innovation, overseas expansion, and compliance with policy development: 1. Innovation: Interest rate-sensitive Innovative Drugs and Medical Devices are expected to continue benefiting from improved liquidity. The bank believes that the main factors driving the development of Innovative Drugs in 2025 will be as follows: (1) Overseas expansion. Due to the pricing disparity between China and the United States.
Kangnuo Ya-B (02162.HK): The latest data from the CM336 Phase I/II clinical research was presented in poster form at the 66th Annual Meeting of the American Society of Hematology (ASH).
On December 9th, Gelonghui reported that KANNUA-B (02162.HK) announced its latest data from the phase I/II clinical study of the BCMAxCD3 bispecific antibody CM336 for the treatment of relapsed or refractory multiple myeloma, which was presented in poster form at the 66th American Society of Hematology (ASH) annual meeting.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
